0000883984-26-000008
SEC filingICU Medical, Inc. reported revenues of $2.23 billion for fiscal year 2025, with gross profit of $822.0 million and net income of $732 thousand. The company generated $179.8 million in operating cash flow, though net cash decreased by $603 thousand due to significant investing and financing activities. Key financial metrics include a gross margin of 36.9% and operating margin of 1.9%. The balance sheet shows total assets of $4.05 billion, with long-term debt of $1.27 billion and stockholders' equity of $2.12 billion. The company's performance was impacted by restructuring and integration expenses of $66.5 million and a gain on disposition of business of $44.8 million.
ICU Medical, Inc. reported fiscal year 2025 revenues of $2.23 billion with cost of goods sold of $1.41 billion, resulting in gross profit of $822.0 million. Operating expenses totaled $779.2 million, including selling, general and administrative expenses of $625.2 million, research and development of $87.5 million, and restructuring, strategic transaction and integration expenses of $66.5 million. This yielded income from operations of $42.8 million. After interest expense of $83.0 million, other expenses of $232 thousand, a gain on disposition of business of $44.8 million, and income tax provision of $2.4 million, the company reported net income of $732 thousand. The company's operating cash flow was $179.8 million, while investing activities used $122.2 million and financing activities used $311.5 million, resulting in a net cash decrease of $603 thousand.
The filing does not provide segment breakdown or geographic mix data for revenue analysis. The total revenue of $2.23 billion represents the company's consolidated performance across all business activities. No specific growth drivers or segment performance details are disclosed in the provided financial data. The company's revenue generation appears to be from its core medical device operations, but without segment disclosure, detailed revenue composition analysis is not possible based on the available information.
The company achieved a gross margin of 36.9% ($822.0 million gross profit on $2.23 billion revenue). Operating margin was 1.9% ($42.8 million operating income on $2.23 billion revenue). The cost structure shows significant selling, general and administrative expenses of $625.2 million (28.0% of revenue) and research and development expenses of $87.5 million (3.9% of revenue). Restructuring, strategic transaction and integration expenses of $66.5 million (3.0% of revenue) impacted profitability. The company's net income margin was minimal at 0.03% ($732 thousand on $2.23 billion revenue).
The company generated $179.8 million in operating cash flow, with key adjustments including depreciation and amortization of $200.7 million and stock compensation of $55.8 million. Investing activities used $122.2 million, primarily for purchases of property, plant and equipment ($88.0 million) and intangible asset additions ($9.0 million), partially offset by proceeds from divestiture of businesses ($211.2 million). Financing activities used $311.5 million, mainly for repayments of long-term obligations ($302.8 million) and purchase of treasury stock ($8.8 million). The balance sheet shows total assets of $4.05 billion, including current assets of $1.19 billion, property, plant and equipment of $451.8 million, goodwill of $1.50 billion, and intangible assets of $633.6 million. Total liabilities are $1.93 billion, with long-term debt of $1.27 billion and current liabilities of $498.9 million. Stockholders' equity is $2.12 billion, resulting in a debt-to-equity ratio of 0.60.
The filing does not provide management guidance, strategic priorities, or specific risk factors in the provided financial data. No forward-looking statements or outlook information is included in the extracted financial statements. The company's financial performance shows ongoing restructuring and integration activities, as evidenced by the $66.5 million in related expenses. The gain on disposition of business of $44.8 million suggests portfolio optimization activities. The company maintains substantial liquidity with $308.0 million in cash and cash equivalents, though the net cash decrease of $603 thousand indicates cash flow challenges from significant debt repayments and capital expenditures.